Pancreatic Neoplasms
Conditions
Keywords
pancreatic mass, pancreatic solid mass, pancreatic lesion
Brief summary
This is a randomized trial to evaluate and directly compare the tissue quality, diagnostic sucess and safety profile of four different Fine Needle Biopsy needles.
Detailed description
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is currently the standard method for sampling solid pancreatic masses, with reported sensitivity for malignant cytology of 85-95%, specificity of 95-98% and diagnostic accuracy of 78-95%. Diagnostic failure of EUS-FNA can be due to inadequate targeting, inexperience of the endoscopist/pathologist, or necrotic or fibrotic tumors in which viable cells are difficult to obtain. The cellularity and architectural representation of the sample can also be determined by the needle used and its specific features. Recently, new needles known as fine needle biopsy (FNB) needles have become available that are specially designed to promote the collection of core tissue by unique designs of their needle tips. The advantages of FNB over FNA needles are that (a) the quality of tissue procured is superior: FNA needles yield cytology whereas FNB needles yield histology (b) molecular marker analysis can be performed more reliably on histology samples than cytology aspirates and (c) as histological tissue is greater in quantity than cytological aspirates, a quicker diagnosis with fewer passes can be established by histology than cytology. Four different types of FNB needles are currently available - reverse-bevel tip (EchoTip ProCore HD Ultrasound Biopsy Needle, Cook Medical, Bloomington, IN), Menghini-tip (EZ shot, Olympus America, Center Valley, PA), Franseen tip (Acquire, Boston Scientific Corporation, Natick, MA) and fork-tip (SharkCore, Medtronic Corporation/Covidien, Newton, MA) needles, each with unique tip designs to facilitate procurement of histological core tissue. Although we have previously compared in randomized trials the diagnostic yield of Franseen and fork-tip FNB needles and have shown the two needles to be equivalent, there are currently no randomized trials directly comparing all four FNB needle types. EUS-guided tissue acquisition can also be performed using different techniques, including the use of suction, no use of suction and the stylet retraction technique. There are currently no studies comparing these different tissue acquisition techniques using the different FNB needles and no study has demonstrated the best technique for FNB.
Interventions
DIAGNOSTIC_TESTSolid pancreatic mass lesion biopsy
The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
Sponsors
AdventHealth
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Masking description
The patients, pathologists assessing the biopsy specimens and the research staff responsible for follow-up will be blinded to the FNB needle type utilized. Data will also be blinded for statistical analysis.
Intervention model description
This is a randomized trial comparing four types of FNB needles and three sampling techniques. Patients will be randomized to one of the four different FNB needles. All patients will then undergo FNB using the specified needle and all three sampling techniques (one pass per technique using the assigned needle).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All patients referred for EUS-guided tissue acquisition of suspected or confirmed solid pancreatic mass lesions visualized on any radiological imaging 2. Able and willing to provide written or verbal consent 3. ≥ 18 years old 4. Able to undergo conscious sedation for EUS procedure
Exclusion criteria
1. \<18 years old 2. Unable to obtain informed consent from the patient 3. Medically unfit for sedation 4. Pregnant patients 5. No pancreatic mass lesions visualized on EUS 6. Irreversible coagulopathy as determined by platelet count \< 50,000/microL or International Normalized Ratio (INR) \> 1.5 7. Unable to stop anti-platelet agents prior to the procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Degree of cellularity in biopsy sample | 3 days | Compare the degree of cellularity of the obtained tissue in the biopsy sample between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques. Cellularity is defined as the proportion of core tissue to total specimen area. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Specimen bloodiness in biopsy sample | 1 day | Measured as the area of bloodiness in the biopsy sample, with calculation as a percentage in the microscopic field. |
| Presence of crush artefact in biopsy sample | 1 day | Documenting the presence or absence of crush artefact in the biopsy sample. If present, it is measured as the area of artefact in biopsy sample, with calculation as a percentage in relation to the total sample area. |
| Diagnostic adequacy of the biopsy sample | 1 day | Documentation of the presence of adequate tissue material (pancreatic parenchyma and tumor if applicable) in the biopsy sample. |
| Adverse events | 7 days, 30 days, and 6 months | The subject will be asked to report and medical records will be reviewed for any adverse events related to the procedure or the underlying disease. |
| Diagnostic operating characteristics | 6 months | Compare the diagnostic operating characteristics of the biopsy sample and detection of neoplasia (defined as sensitivity, specificity, negative predictive value, positive predictive value and accuracy) between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques |
| Technical failure | 1 day | Measured as the inability to successfully perform the fine needle biopsy using the assigned needle, due to any needle dysfunction. |
Countries
United States
Contacts
Primary ContactShyam Varadarajulu, MD
Backup ContactRobin Barron-Nelson
Outcome results
None listed